DeteksiDini
Detect cancer early from urine with DeteksiDini.
Model
Services
Industry
Health Care
Stage
Idea
Location
Indonesia
VentureGrade
24
out of 100
DeteksiDini is a non-invasive cancer screening method that detects cancer from stage 0 using urine samples and C. elegans, enabling early intervention.
Elevator Pitch
Cancer is one of the top five critical illnesses in Indonesia, with a significantly high mortality rate. Early detection is crucial for effective treatment, yet current diagnostic methods fail to identify cancer at its earliest stages. DeteksiDini offers a breakthrough solution—using volatile organic compounds (VOCs) in urine and the unique sensing ability of C. elegans worms, it detects cancer from stage 0. Patients can easily collect samples at home and send them to our lab. With Indonesia’s 2024–2034 National Cancer Control Plan prioritizing early detection, DeteksiDini is poised to become a game-changer to save lives.
Founder (s)
Revenue Model
DeteksiDini serves individuals, corporations, and medical centers. Screening for four cancer types costs IDR 2,500,000. Individuals can choose a one-time test or biannual subscription with a 5% discount. Corporate and medical center partners receive 10% employee discounts. Strategic partnerships drive growth, brand visibility, and long-term adoption of early detection.
Startup Journey
Two years ago, I lost my father to cancer that was detected too late. Despite over 20 years in cancer research, I realized I hadn’t used my knowledge to make a direct impact. This loss became my turning point. I aim to launch DeteksiDini, an affordable early cancer diagnostic service for Indonesia, where high screening costs and limited early detection tools hinder timely diagnosis. I partnered with Dr. Ratna, an expert in R&D and clinical development, to strengthen DeteksiDini’s capabilities and ensure regulatory compliance. We selected a C. elegans-based method for its proven sensitivity, specificity, and cost-efficiency—vital for Indonesia’s healthcare landscape. The technology is already validated and in clinical use in Japan, demonstrating strong potential. We are now focused on partnering with Hirotsu Bio Science, securing funding for lab setup, and building a local team. With the right support, DeteksiDini will redefine cancer screening and save lives across Indonesia.
Go-To-Market Plan
DeteksiDini will leverage social media to engage individual customers and form strategic partnerships with medical centers and corporations. To ease the financial burden, we’ll collaborate with CareNow, enabling patients to pay screening costs in installments, making early cancer detection more accessible and affordable.
Potential Exit
The most likely exit strategy for DeteksiDini is acquisition by PT Kalbe Farma Tbk or Prodia, both of which have strong oncology portfolios, a history of strategic collaborations, and the capacity for innovation and market expansion. These leaders in Indonesia’s diagnostic sector are well-positioned to scale DeteksiDini’s impact.
VentureGrade℠
